A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus
Clinical trial NCT03333317 · TERMINATED
Trial details
- NCT number
- NCT03333317
- Sponsor
- Janssen Research & Development, LLC
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-24
- Primary completion
- 2018-03-23
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.